GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (FRA:RFS) » Definitions » Cyclically Adjusted Price-to-FCF

Resverlogix (FRA:RFS) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Resverlogix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Cyclically Adjusted Price-to-FCF Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Resverlogix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Resverlogix's Cyclically Adjusted Price-to-FCF falls into.



Resverlogix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Resverlogix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Resverlogix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.011/125.0724*125.0724
=-0.011

Current CPI (Dec. 2023) = 125.0724.

Resverlogix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201310 -0.043 97.182 -0.055
201401 -0.018 97.261 -0.023
201404 -0.022 98.920 -0.028
201407 -0.017 99.315 -0.021
201410 -0.020 99.473 -0.025
201501 -0.041 98.209 -0.052
201504 -0.023 99.710 -0.029
201507 -0.044 100.579 -0.055
201510 -0.024 100.500 -0.030
201601 -0.092 100.184 -0.115
201604 -0.036 101.370 -0.044
201607 -0.026 101.844 -0.032
201610 -0.076 102.002 -0.093
201701 -0.071 102.318 -0.087
201704 -0.031 103.029 -0.038
201707 -0.066 103.029 -0.080
201710 -0.030 103.424 -0.036
201801 -0.051 104.056 -0.061
201804 -0.018 105.320 -0.021
201807 -0.104 106.110 -0.123
201810 -0.045 105.952 -0.053
201901 -0.041 105.557 -0.049
201904 -0.043 107.453 -0.050
201907 -0.042 108.243 -0.049
201910 -0.025 107.927 -0.029
202001 -0.003 108.085 -0.003
202004 -0.003 107.216 -0.003
202007 -0.005 108.401 -0.006
202010 -0.007 108.638 -0.008
202103 -0.003 110.298 -0.003
202106 -0.018 111.720 -0.020
202109 -0.009 112.905 -0.010
202112 -0.001 113.774 -0.001
202203 -0.005 117.646 -0.005
202206 -0.005 120.806 -0.005
202209 -0.007 120.648 -0.007
202212 0.001 120.964 0.001
202306 0.000 124.203 0.000
202309 0.000 125.230 0.000
202312 -0.011 125.072 -0.011

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix  (FRA:RFS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Resverlogix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Resverlogix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (FRA:RFS) Business Description

Industry
Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix (FRA:RFS) Headlines

No Headlines